CVS Health (CVS) 10-Q2023 Q2 Quarterly report

Filed: 2 Aug 23, 6:36am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Bad

New words: Allison, constituted, defense, discrimination, efficiency, Exhibit, expiration, free, fundamental, incentive, instruction, Maryland, outpatient, outplacement, page, peptide, PHE, prorated, repaid, repay, resumption, salary, simplify, softening, thousand, transportation, workplace

Removed: divided, enter, Indian, insulin, Judicial, Panel, presumptively, strong

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated CVS transcripts

CVS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 15.1

Letter re: Unaudited Interim Financial Information

August 2, 2023

To the Shareholders and the Board of Directors of CVS Health Corporation

We are aware of the incorporation by reference in the Registration Statements (Form S-3ASR No. 333-272200 and Form S-8 Nos. 333-271582, 333-270936, 333-238507, 333-230035, 333-228622, 333-167746, 333-217853, 333-208805, 333-141481, 333-139470, 333-63664, 333-91253, 333-49407, 333-34927, and 333-28043) of CVS Health Corporation of our report dated August 2, 2023, relating to the unaudited condensed consolidated interim financial statements of CVS Health Corporation that is included in its Form 10-Q for the quarter ended June 30, 2023.

/s/ Ernst & Young LLP

Boston, Massachusetts

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.